



## CLOVIS ONCOLOGY CORPORATE PROFILE

**Clovis Oncology** is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets.

Clovis' development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drug to the right patient at the right time – represents the future of cancer therapy.

*We have one marketed product, **Rubraca® (rucaparib)**.*

*For information on our marketed product, [click here](#).*

Our lead product candidate under active development is rucaparib, an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1, 2 and 3. Rucaparib is in advanced clinical development for the treatment of ovarian cancer and we are initiating clinical development for the treatment of metastatic castration-resistant prostate cancer patients. We maintain global rights to rucaparib.